We’re passionate about improving the quality of life for people with solid cancer
Cartherics aims for a better quality of life for cancer patients with its CAR-iNK technologies aimed at enabling better, lower cost and more accessible treatment for patients.
Immunotherapy in oncology is globally recognized as a revolutionary therapeutic modality with enormous potential.
Join a team that’s helping drive this new field.
People & Careers News
Cartherics COO Dr Ian Nisbet on the promise of CAR-NK cells for cancer and endometriosis at BIO 2025
In the lead-up to BIO, Cartherics’ COO, Dr Ian Nisbet was interviewed by BioSpectrum Asia to discuss the company’s innovative [...]
Cartherics’ appointment of Laurence Nore underscores a growing trend with global implications. As global demand for biotechnology products and services [...]
Today on World Ovarian Cancer Day, we are proud to share the powerful story of Heather Hawkins - ovarian cancer [...]
Cartherics appoints Prof. Bryan Williams as new Board Chair and Ms. Laurence Nore as Non-Executive Director Melbourne, Australia, 16 April [...]
Cartherics is pleased to announce that it has made several strategic new appointments to enhance its scientific and manufacturing teams, [...]
As we reflect on 2024, it's clear that this year has been a defining chapter in Cartherics' 10-year history. We've [...]
We are pleased to announce that Cartherics’ CEO, Prof. Alan Trounson has been recognised as a ScholarGPS Highly Ranked Scholar [...]
Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by Barbara Barkhausen, a German speaking, Asia-Pacific Correspondent for a variety of [...]
Melbourne, Australia, 17 October 2023 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for [...]
Commercialising science and technology is key to the continued growth of Australia’s vibrant life sciences industry. Translating research into real-world [...]
